Growth hormone and hexarelin prevent endothelial vasodilator dysfunction in aortic rings of the hypophysectomized rat

J Cardiovasc Pharmacol. 1999 Sep;34(3):454-60. doi: 10.1097/00005344-199909000-00021.

Abstract

The endothelial vasodilation mechanism(s) has been investigated in aortic rings of hypophysectomized male rats as well as hypophysectomized rats treated for 7 days with growth hormone (GH, 400 microg/kg, s.c.) or hexarelin (80 microg/kg, s.c.). Tissue preparations from intact animals were taken as controls. The results obtained indicate that the release of 6-keto-prostaglandin F1alpha (6-keto-PGF1alpha) from aortic rings of hypophysectomized rats was markedly reduced (51%; p<0.01) as compared with that of control preparations; the peak response to cumulative concentration of endothelin-1 (ET-1, from 10(-11) to 10(-5) M) was increased 2.4-fold (p<0.01) versus controls; the relaxant activity of acetylcholine (ACh, from 10(-10) to 10(-4) M) in norepinephrine-precontracted aortic rings was reduced by 39.5+/-4.4%. Pretreatment of hypophysectomized rats with GH or hexarelin markedly antagonized the hyperresponsiveness of the aortic tissue to ET-1 and allowed a consistent recovery of both the relaxant activity of ACh and the generation of 6-keto-PGF1alpha. Collectively these findings support the concept that dysfunction of vascular endothelial cells may be induced by a defective GH function. Because a replacement regimen of GH restored the somatotropic function and increased plasma insulin-like growth factor-I (IGF-I) concentrations in the hypophysectomized rats, it is suggested that IGF-I may have protected the vascular endothelium acting as a biologic mediator of GH action. In contrast to GH, hexarelin replacement neither increased body weight nor affected the plasma concentrations of IGF-I, indicating that its beneficial action on vascular endothelium was divorced from that on somatotropic function and was likely due to activation of specific endothelial receptors.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • 6-Ketoprostaglandin F1 alpha / metabolism
  • Acetylcholine / metabolism
  • Animals
  • Aorta
  • Body Weight
  • Endothelin-1 / metabolism
  • Endothelium, Vascular / drug effects
  • Endothelium, Vascular / physiopathology*
  • Enzyme Inhibitors / pharmacology
  • Homeostasis
  • Human Growth Hormone / pharmacology*
  • Humans
  • Hypophysectomy*
  • Male
  • Oligopeptides / pharmacology*
  • Protective Agents / pharmacology
  • Rats
  • Rats, Sprague-Dawley / surgery
  • Vasodilation / drug effects*
  • omega-N-Methylarginine / pharmacology

Substances

  • Endothelin-1
  • Enzyme Inhibitors
  • Oligopeptides
  • Protective Agents
  • hexarelin
  • Human Growth Hormone
  • omega-N-Methylarginine
  • 6-Ketoprostaglandin F1 alpha
  • Acetylcholine